Sunday, October 11, 2026

CBOE Over 5% Up In The Last 24 Hours

CBOE Over 5% Up In The Last 24 Hours

(VIANEWS) - CBOE (VIX) has been up by 5.61% for the last session's close. At 16:08 EST on Monday, 1 April, CBOE (VIX) is $13.74.

CBOE Range

Regarding CBOE's daily highs and lows, it's 7.01% up from its trailing 24 hours low of $12.84 and 4.97% up from its trailing 24 hours high of $13.09.

Concerning CBOE's yearly highs and lows, it's 1.4% up from its 52-week low and 60.8% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a negative 0.47%, a negative 0.05%, and a positive 3.49%, respectively.

CBOE's highest amplitude of average volatility was 1.93% (last week), 2.66% (last month), and 3.49% (last quarter), respectively.

News about

  • Nasdaq 100 monthly forecast: April 2024 - 31 March 2024. According to DailyForex on Sunday, 31 March, "Shorting the NASDAQ 100 has been tantamount to blowing up your account on purpose every time you do it."

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com